Read our latest announcements
Filter by year:
Jim Van heusden is CEO of Karolinska Development, having joined in March 15. He has more than 20 years’ experience in venture capital, and drug development.
Modus Therapeutics AB will be attending BIO-Europe 2015 in Munich, Germany.
Modus Therapeutics today announced that the first patient has been enrolled in the Phase II study with sevuparin in patients with SCD.
Modus Therapeutics AB announces its Chief Executive Officer Christina Herder is to present at Nordic Life Science Days 2015 conference.
Modus Therapeutics AB, a Karolinska Development (STO:KDEV) portfolio company, is set to move headquarters in the coming month.
Modus Therapeutics AB today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for sevuparin (DF02).
Ergomed plc (LSE: ERGO or ‘Ergomed’) and Modus Therapeutics AB (‘Modus Therapeutics’) today announced that they have entered into a co-development agreement.
Modus Therapeutics AB today announced that it has received positive opinion from the Committee for Orphan Medicinal Products on orphan drug designation in the EU for sevuparin.
Sankt Eriksgatan 117,
SE-113 43 Stockholm, Sweden
© 2019 Modus Therapeutics. | All Rights Reserved.